Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia.
about
Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemiasCurrent and future alternative therapies for beta-thalassemia majorCustomizing the genome as therapy for the β-hemoglobinopathiesProfile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromesβ-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapiesHydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias.An international effort to cure a global health problem: A report on the 19th Hemoglobin Switching Conference.Gene therapy for hemoglobinopathies: the state of the field and the future.Hydroxyurea Treatment in Transfusion-Dependent β-Thalassemia PatientsVariation in Gamma-Globin Expression before and after Induction with Hydroxyurea Associated with BCL11A, KLF1 and TAL1.A Novel High-Content Immunofluorescence Assay as a Tool to Identify at the Single Cell Level γ-Globin Inducing Compoundsα-Globin as a molecular target in the treatment of β-thalassemiaAdvances in understanding erythropoiesis: evolving perspectivesNon-transfusion-dependent thalassemias.Regulation of the fetal hemoglobin silencing factor BCL11A.A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in β-thalassaemia intermedia.Cis-vaccenic acid induces differentiation and up-regulates gamma globin synthesis in K562, JK1 and transgenic mice erythroid progenitor stem cells.β -thalassemia intermedia in Northern Iraq: a single center experienceThe effect and side effect of hydroxyurea therapy on patients with β-thalassemia: a systematic review to December 2012.Management of non-transfusion-dependent thalassemia: a practical guide.A complicated disease: what can be done to manage thalassemia major more effectively?Thalassemia 2016: Modern medicine battles an ancient disease.Increasing prevalence of thalassemia in America: Implications for primary care.Revisiting beta thalassemia intermedia: past, present, and future prospects.An enhancer haplotype may influence BCL11A expression levels and the response to hydroxyurea in β-thalassemia patients.Morbidities in non-transfusion-dependent thalassemia.Fetal hemoglobin regulation in β-thalassemia: heterogeneity, modifiers and therapeutic approaches.β-Thalassemia.Clinical and Haematological Effects of Hydroxyurea in β-Thalassemia Intermedia Patients.In Vitro Hb Production in B-thalassemia Patients Is Not a Predictor of Clinical Responsiveness to HydroxyureaInducing indel mutation in the SOX6 Gene by Zinc Finger Nuclease for gamma reactivation: An Approach towards Gene Therapy of Beta Thalassemia.Whole transcriptome analysis of human erythropoietic cells during ontogenesis suggests a role of VEGFA gene as modulator of fetal hemoglobin and pharmacogenomic biomarker of treatment response to hydroxyurea in β-type hemoglobinopathy patientsStress-enhanced translation of γ-globin mRNA.Serum Paraoxonase Activity and Malondialdehyde Serum Concentrations Remain Unaffected in Response to Hydroxyurea Therapy in β-Thalassemia Patients.Current Standards of Care and Long Term Outcomes for Thalassemia and Sickle Cell Disease.Whole-exome sequencing identifies an α-globin cluster triplication resulting in increased clinical severity of β-thalassemia.Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management.Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients.Induction of foetal haemoglobin synthesis in erythroid progenitor stem cells: mediated by water-soluble components of Terminalia catappa.Hydroxyurea for hemoglobin E/β-thalassemia: a systematic review and meta-analysis.
P2860
Q24187646-B9BFE5E5-D8D8-4685-A0F5-B8134488451EQ26750906-A7024687-766C-4755-AB20-2D55A919B6D7Q26751061-CEFD89C7-988F-4DF3-B4EE-6A005113B1E4Q26771519-40B6695B-9635-4C3D-AB0F-98E2CC73FBA0Q28086960-7F505A08-65A4-4D26-9214-40B9CABB5641Q33436115-32482DD1-BE2E-42F2-8B23-1AB18B6BC6AAQ33850615-4E7656BB-43B8-4962-BD25-1591BFFC96BBQ34204480-3700A73E-5231-4DF1-A21E-2B41741160F2Q35213992-2B649162-7945-4756-B6E9-7CD0C275AFCEQ35656305-DAD1C902-7BE8-4210-8E78-BDC2BB83271CQ35824056-46B8EB76-195E-40A1-9A6A-7DFBDA04D071Q35836891-0339DE91-4ECD-4317-ACAF-B66C881B5216Q36803829-EDF61BB0-79F8-4EEF-AB00-5E2EB4DAD824Q36892558-7282F51A-346C-47CF-9491-41F162B50F55Q36909390-3EB8BEE5-43C3-4212-8C55-E349C3492A04Q37524883-5C418A19-D188-4500-B09F-19DDF9EF8AC0Q37585749-12A2A3F3-C935-4A3B-BEC0-DBB1BC197809Q37639833-65F6FFEE-3D44-424C-9CD5-C0D1B0742281Q38229328-1C84D05B-8731-49E0-8BAC-F621541A839EQ38254291-65FEDD2E-72E0-4272-882A-0B927E329A82Q38607875-9BC90464-C2FA-4B6F-9CC4-23EE331A8857Q38625435-F6C46EBA-454D-496E-95F3-70573EE87C48Q38626123-1FF32156-2DF6-43FB-9051-777F68A26C9FQ38673817-86851F35-ACDE-4118-8BA8-6D34101A720AQ38714401-5000BDD4-CEDD-406D-A326-7640CD03B824Q38836177-75E4A28A-85F0-435B-B16E-F7C80771457BQ38995849-99B7CAC5-D8E4-4D92-870E-A19C6F4AF044Q38998151-C3C0D838-D38A-4A34-9C60-DB8E044C80EEQ40334323-B2A066F9-F195-41F0-BB8A-9987A5260D8BQ41466551-3AAA97CD-F6CC-41B0-B2C0-6694D0DF4A63Q41931448-BBCFB6D8-2A4F-473A-9769-01D846996CDDQ42643812-81F0BD7A-8AD6-484B-BC95-47EA3E13B3ECQ42959483-A107B50F-C326-4E74-80F1-960DF5FF6226Q46633489-A4471C78-AB16-4F97-AC2D-363D500903CFQ47103242-48EE152C-06AD-4A8C-B87A-BBC74D701F86Q47131108-47575155-A2F5-4931-A046-8002C6C97592Q47742744-681B129C-38FC-4306-8589-7A2CD524A5BDQ47828342-9562A111-8EB1-4773-8AC2-7C58430B0D14Q47924851-ACF86BD6-07B8-401C-A289-39D4EBD806A8Q47980084-F0DE8867-78EF-47F1-97D5-CA5A03C54581
P2860
Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Clinical experience with fetal ...... n patients with β-thalassemia.
@en
type
label
Clinical experience with fetal ...... n patients with β-thalassemia.
@en
prefLabel
Clinical experience with fetal ...... n patients with β-thalassemia.
@en
P2093
P1433
P1476
Clinical experience with fetal ...... in patients with β-thalassemia
@en
P2093
Ali T Taher
Khaled M Musallam
Vijay G Sankaran
P304
2199-212; quiz 2372
P356
10.1182/BLOOD-2012-10-408021
P407
P577
2013-01-11T00:00:00Z